Xenon Pharmaceuticals Inc. - Common Stock (XENE)

CUSIP: 98420N105

Q2 2023 13F Holders as of 30 Jun 2023

Type / Class
Equity / Common Stock
Shares outstanding
76,851,274
Total 13F shares
61,306,738
Share change
+191,364
Total reported value
$2,360,645,061
Put/Call ratio
128%
Price per share
$38.50
Number of holders
173
Value change
+$10,880,022
Number of buys
88
Number of sells
74

Quarterly Holders Quick Answers

What is CUSIP 98420N105?
CUSIP 98420N105 identifies XENE - Xenon Pharmaceuticals Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q2 2023

As of 30 Jun 2023, Xenon Pharmaceuticals Inc. - Common Stock (XENE) was held by 173 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 61,306,738 shares. The largest 10 holders included FMR LLC, Avoro Capital Advisors LLC, Driehaus Capital Management LLC, Polar Capital Holdings Plc, Capital International Investors, MARSHALL WACE, LLP, Capital World Investors, PICTET ASSET MANAGEMENT SA, LORD, ABBETT & CO. LLC, and COMMODORE CAPITAL LP. This page lists 174 institutional shareholders reporting positions in this security for the Q2 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.